1
9.42
0.31 (3.40%)
| Previous Close | 9.11 |
| Open | 9.38 |
| Volume | 5,012,032 |
| Avg. Volume (3M) | 3,621,336 |
| Market Cap | 1,159,922,304 |
| Price / Sales | 2.28 |
| Price / Book | 2.04 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -25.14% |
| Operating Margin (TTM) | -31.33% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Total Debt/Equity (MRQ) | 11.33% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | 56.74 M |
| Levered Free Cash Flow (TTM) | 95.16 M |
| Return on Assets (TTM) | -12.43% |
| Return on Equity (TTM) | -22.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | 10x Genomics, Inc. | Bearish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 102.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Venrock Management Vi, Llc | 30 Sep 2024 | 2,106,757 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Morgan Stanley, 91.08%) | Buy |
| Median | 13.00 (38.00%) | |
| Low | 6.50 (Goldman Sachs, -31.00%) | Sell |
| Average | 12.56 (33.33%) | |
| Total | 4 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 9.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 26 Jun 2025 | 13.00 (38.00%) | Hold | 11.70 |
| Barclays | 24 Jun 2025 | 13.00 (38.00%) | Buy | 10.89 |
| 10 Apr 2025 | 12.00 (27.39%) | Buy | 7.70 | |
| Morgan Stanley | 19 May 2025 | 18.00 (91.08%) | Buy | 8.93 |
| Stephens & Co. | 15 May 2025 | 14.00 (48.62%) | Buy | 9.20 |
| UBS | 13 May 2025 | 12.00 (27.39%) | Hold | 9.65 |
| Canaccord Genuity | 12 May 2025 | 15.00 (59.24%) | Buy | 9.49 |
| Goldman Sachs | 12 May 2025 | 6.50 (-31.00%) | Sell | 9.49 |
| JP Morgan | 09 May 2025 | 9.00 (-4.46%) | Hold | 8.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2025 | Announcement | 10x Genomics Announces Patent Litigation Settlement Agreement with Bruker |
| 08 May 2025 | Announcement | 10x Genomics Reports First Quarter 2025 Financial Results |
| 30 Apr 2025 | Announcement | 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference |
| 14 Apr 2025 | Announcement | 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |